Production (Stage)
Quoin Pharmaceuticals, Ltd.
QNRX
$8.74
$0.212.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.11% | -3.08% | -3.64% | -6.77% | -10.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.70% | 1.60% | 1.02% | -5.41% | -8.08% |
| Operating Income | -21.70% | -1.60% | -1.02% | 5.41% | 8.08% |
| Income Before Tax | -24.21% | -3.18% | -0.73% | 15.02% | 18.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.21% | -3.18% | -0.73% | 15.02% | 18.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.21% | -3.18% | -0.73% | 15.02% | 18.36% |
| EBIT | -21.70% | -1.60% | -1.02% | 5.41% | 8.08% |
| EBITDA | -21.98% | -1.66% | -1.07% | 5.44% | 8.15% |
| EPS Basic | 80.80% | 77.40% | 69.22% | 50.54% | 19.57% |
| Normalized Basic EPS | 80.80% | 77.40% | 69.22% | 50.54% | 19.57% |
| EPS Diluted | 80.72% | 77.34% | 69.19% | 50.54% | 19.57% |
| Normalized Diluted EPS | 80.80% | 77.40% | 69.22% | 50.54% | 19.57% |
| Average Basic Shares Outstanding | 633.79% | 421.01% | 337.75% | 350.43% | 387.21% |
| Average Diluted Shares Outstanding | 636.59% | 424.14% | 345.83% | 362.50% | 412.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |